Gardasil
Cervical Cancer
Murdoch Childrens Research InstitutevaccinePhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 65/ 100
Competitive context
160 Active assets in the Cervical Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine UNICANCER | Phase 2 | BBB |
Indocyanine Green Istanbul University | Phase 4 | BB |
Tisotumab Vedotin Seagen Inc. | Phase 2 | BB |
Carboplatin Merck Sharp & Dohme LLC | Phase 3 | B |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 3 | B |
View all 50 →
Same molecule, other indications
Gardasil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →